Tyra Biosciences Inc (TYRA)

May 12, 2025, 4:05 PM EDT - 22 days ago

Tyra Biosciences to Participate at Upcoming Investor Conferences

May 8, 2025, 4:05 PM EDT - 26 days ago

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

Mar 27, 2025, 4:05 PM EDT - 2 months ago

Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

Feb 11, 2025, 4:05 PM EST - 4 months ago

Tyra Biosciences to Present at Upcoming Investor Conferences

Jan 22, 2025, 8:00 AM EST - 4 months ago

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

Jan 10, 2025, 8:00 AM EST - 5 months ago

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

Nov 7, 2024, 4:05 PM EST - 7 months ago

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

Oct 28, 2024, 7:00 AM EDT - 7 months ago

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Oct 25, 2024, 11:34 AM EDT - 7 months ago

Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday?

Oct 24, 2024, 6:21 PM EDT - 7 months ago

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Oct 23, 2024, 4:05 PM EDT - 7 months ago

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

Oct 21, 2024, 7:55 AM EDT - 8 months ago

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

Oct 18, 2024, 2:34 PM EDT - 8 months ago

BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug

Oct 18, 2024, 9:51 AM EDT - 8 months ago

This Datadog Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

DDOG ACI ECL VCTR

Oct 11, 2024, 8:00 AM EDT - 8 months ago

Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)

Sep 12, 2024, 11:00 AM EDT - 9 months ago

The Schall Law Firm Is Looking Into Tyra Biosciences Inc For Possibly Violating Securities Laws And The Firm Seeks Shareholder Participation

Sep 11, 2024, 4:05 PM EDT - 9 months ago

Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference

Sep 11, 2024, 4:00 AM EDT - 9 months ago

Tyra Biosciences, Inc. May Have Defrauded Shareholders And Impacted Individuals Are Invited To Join The Schall Law Firm's Investigation

Sep 10, 2024, 4:05 PM EDT - 9 months ago

Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer

Sep 9, 2024, 11:00 AM EDT - 9 months ago

Tyra Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Wants Shareholders To Participate

Sep 7, 2024, 11:00 AM EDT - 9 months ago

Fraudulent Practices May Have Been Committed By Tyra Biosciences Inc And Affected Investors Are Urged To Reach Out To The Schall Law Firm

Sep 6, 2024, 11:00 AM EDT - 9 months ago

Investors Are Invited By The Schall Law Firm To Partake In An Inquiry In Tyra Biosciences, Inc's Possible Violations Of Securities Regulations

Sep 5, 2024, 11:00 AM EDT - 9 months ago

Tyra Biosciences, Inc. Is Being Looked Into For Acting Wrongfully And The Schall Law Firm Has Launched An Investigation That Shareholders Can Join

Sep 4, 2024, 11:00 AM EDT - 9 months ago

The Schall Law Firm Is Looking Into Tyra Biosciences Inc. For Possible Securities Related Infractions And Stockholders Can Assist

Sep 2, 2024, 11:00 AM EDT - 9 months ago

Tyra Biosciences Inc Stockholders Can Partake In An Inquiry Into Whether The Company Defrauded The Public

Sep 1, 2024, 11:00 AM EDT - 9 months ago

Attention Investors: The Schall Law Firm Is Looking Into Tyra Biosciences Inc. For Potentially Violating Securities Laws And Investors Can Reach Out

Aug 31, 2024, 11:00 AM EDT - 9 months ago

An Inquiry Is Being Made Into Whether Tyra Biosciences Has Defrauded The Public And The Schall Law Firm Wants Shareholders To Help

Aug 30, 2024, 11:00 AM EDT - 9 months ago

Tyra Biosciences May Have Broken Securities Laws And Impacted Stakeholders Are Urged To Lend A Hand To The Schall Law Firm's Inquiry

Aug 29, 2024, 11:00 AM EDT - 9 months ago

The Public Is Encouraged To Reach Out To The Schall Law Firm About An Inquiry Into Tyra Biosciences Inc.'s Potentially Fraudulent Actions

Aug 28, 2024, 11:00 AM EDT - 9 months ago

The Schall Law Firm Invites Investors In Tyra Biosciences Inc To Partake In An Investigation Into Securities Fraud

Aug 27, 2024, 11:00 AM EDT - 10 months ago

An Inquiry Has Been Opened Into Tyra Biosciences Inc's Possible Securities Related Impropriety And Impacted Stakeholders Should Join

Aug 25, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Is Inquiring Into Tyra Biosciences Inc.'s Potential Securities Fraud And Affected Investors Can Participate

Aug 24, 2024, 11:00 AM EDT - 10 months ago

Tyra Biosciences Inc. Shareholders Can Reach Out To The Schall Law Firm About An Investigation Into Possible Breaches Of Securities Laws

Aug 23, 2024, 11:00 AM EDT - 10 months ago

Investors With Losses In Tyra Biosciences Inc. Are Urged To Join An Inquiry Into Possible Securities Fraud With The Schall Law Firm

Aug 21, 2024, 10:15 PM EDT - 10 months ago

Tyra Biosciences Inc. Shareholders Encouraged To Participate In Securities Fraud Investigation With The Schall Law Firm

Aug 21, 2024, 4:30 PM EDT - 10 months ago

The Schall Law Firm Invites TYRA Stakeholders To Be A Part Of A Securities Fraud Investigation Into Tyra Biosciences, Inc.

Aug 20, 2024, 8:37 PM EDT - 10 months ago

TYRA Investors Have Opportunity to Join Tyra Biosciences, Inc. Securities Fraud Investigation with the Schall Law Firm